Eur Heart J. 1987 Oct;8(10):1056-64.
The Lopressor Intervention Trial (LIT) was a double-blind, randomized, placebo-controlled, multicentre study designed to evaluate the effect of oral metoprolol on overall mortality in patients surviving a recent acute myocardial infarction. Patient enrollment began in August 1979 and ended on 15 April 1982, with 2395 patients (1200 on placebo and 1195 on metoprolol). Hospitalized patients, 45 to 74 years of age, began therapy from 6 to 16 days after their myocardial infarction. Following a short titration period, maintenance therapy with metoprolol 100 mg b.i.d. or placebo was continued for up to 1 year. Enrollment was prematurely terminated because of a progressive and marked decline in patient accession; it was not feasible to reach the original goal of 3200 patients in a practical period of time. This target sample size was based on an anticipated 1 year placebo mortality rate of 10%, a 50% reduction in total mortality with metoprolol and premature discontinuation of study medication in no more than 15% of patients in the metoprolol group. Two primary analyses were planned: total mortality among all randomized patients at 7 and at 12 months of trial entry. After 7 months of treatment there were 54 deaths in the placebo group and 42 deaths in the metoprolol group. After 1 year there were 62 deaths in the placebo group and 65 in the metoprolol group. Thus, the 1 year placebo mortality rate of 5.2% was half that predicted at the outset. In addition, study medication was prematurely discontinued in over 30% of patients in the metoprolol group.(ABSTRACT TRUNCATED AT 250 WORDS)
洛普雷斯干预试验(LIT)是一项双盲、随机、安慰剂对照的多中心研究,旨在评估口服美托洛尔对近期急性心肌梗死存活患者总体死亡率的影响。患者招募于1979年8月开始,1982年4月15日结束,共有2395名患者(1200名服用安慰剂,1195名服用美托洛尔)。45至74岁的住院患者在心肌梗死后6至16天开始治疗。经过短暂的滴定期后,继续使用美托洛尔100 mg每日两次或安慰剂进行维持治疗,最长持续1年。由于患者入组人数逐渐显著下降,招募提前终止;在实际时间段内达到3200名患者的原始目标是不可行的。这个目标样本量是基于预期的1年安慰剂死亡率10%、美托洛尔使总死亡率降低50%以及美托洛尔组不超过15%的患者提前停用研究药物。计划进行两项主要分析:所有随机分组患者在试验入组7个月和12个月时的总死亡率。治疗7个月后,安慰剂组有54例死亡,美托洛尔组有42例死亡。1年后,安慰剂组有62例死亡,美托洛尔组有65例死亡。因此,1年安慰剂死亡率5.2%仅为最初预测值的一半。此外,美托洛尔组超过30%的患者提前停用了研究药物。(摘要截短至250字)